Report cover image

Global Ganciclovir Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 16, 2025
Length 191 Pages
SKU # APRC20280660

Description

Summary

According to APO Research, the global Ganciclovir market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Ganciclovir is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Ganciclovir is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Ganciclovir market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Ganciclovir is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Ganciclovir market include Bausch & Lomb, Fresenius Kabi, HUBEI KEYI, Luitpold, Tiantianming, Huatai Pharmaceutical, Tungshun Group, Roche and Luoxin, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Ganciclovir, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Ganciclovir, also provides the sales of main regions and countries. Of the upcoming market potential for Ganciclovir, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Ganciclovir sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Ganciclovir market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Ganciclovir sales, projected growth trends, production technology, application and end-user industry.

Ganciclovir Segment by Company

Bausch & Lomb
Fresenius Kabi
HUBEI KEYI
Luitpold
Tiantianming
Huatai Pharmaceutical
Tungshun Group
Roche
Luoxin
Wuhan Hualong Bio-pharmaceutical
Ganciclovir Segment by Type

Injection
Oral
Ganciclovir Segment by Application

AIDS
CMV Infection
Malignant neoplasms
Tube transplant
Ganciclovir Segment by Region

North America

United States
Canada
Europe

Germany
France
U.K.
Italy
Netherlands
Asia-Pacific

China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America

Mexico
Brazil
Argentina
Middle East & Africa

Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Ganciclovir status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Ganciclovir market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Ganciclovir significant trends, drivers, influence factors in global and regions.
6. To analyze Ganciclovir competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ganciclovir market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Ganciclovir and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ganciclovir.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Ganciclovir market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Ganciclovir industry.
Chapter 3: Detailed analysis of Ganciclovir manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Ganciclovir in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Ganciclovir in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

191 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Ganciclovir Sales Value (2020-2031)
1.2.2 Global Ganciclovir Sales Volume (2020-2031)
1.2.3 Global Ganciclovir Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Ganciclovir Market Dynamics
2.1 Ganciclovir Industry Trends
2.2 Ganciclovir Industry Drivers
2.3 Ganciclovir Industry Opportunities and Challenges
2.4 Ganciclovir Industry Restraints
3 Ganciclovir Market by Company
3.1 Global Ganciclovir Company Revenue Ranking in 2024
3.2 Global Ganciclovir Revenue by Company (2020-2025)
3.3 Global Ganciclovir Sales Volume by Company (2020-2025)
3.4 Global Ganciclovir Average Price by Company (2020-2025)
3.5 Global Ganciclovir Company Ranking (2023-2025)
3.6 Global Ganciclovir Company Manufacturing Base and Headquarters
3.7 Global Ganciclovir Company Product Type and Application
3.8 Global Ganciclovir Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Ganciclovir Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Ganciclovir Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Ganciclovir Market by Type
4.1 Ganciclovir Type Introduction
4.1.1 Injection
4.1.2 Oral
4.2 Global Ganciclovir Sales Volume by Type
4.2.1 Global Ganciclovir Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Ganciclovir Sales Volume by Type (2020-2031)
4.2.3 Global Ganciclovir Sales Volume Share by Type (2020-2031)
4.3 Global Ganciclovir Sales Value by Type
4.3.1 Global Ganciclovir Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Ganciclovir Sales Value by Type (2020-2031)
4.3.3 Global Ganciclovir Sales Value Share by Type (2020-2031)
5 Ganciclovir Market by Application
5.1 Ganciclovir Application Introduction
5.1.1 AIDS
5.1.2 CMV Infection
5.1.3 Malignant neoplasms
5.1.4 Tube transplant
5.2 Global Ganciclovir Sales Volume by Application
5.2.1 Global Ganciclovir Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Ganciclovir Sales Volume by Application (2020-2031)
5.2.3 Global Ganciclovir Sales Volume Share by Application (2020-2031)
5.3 Global Ganciclovir Sales Value by Application
5.3.1 Global Ganciclovir Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Ganciclovir Sales Value by Application (2020-2031)
5.3.3 Global Ganciclovir Sales Value Share by Application (2020-2031)
6 Ganciclovir Regional Sales and Value Analysis
6.1 Global Ganciclovir Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Ganciclovir Sales by Region (2020-2031)
6.2.1 Global Ganciclovir Sales by Region: 2020-2025
6.2.2 Global Ganciclovir Sales by Region (2026-2031)
6.3 Global Ganciclovir Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Ganciclovir Sales Value by Region (2020-2031)
6.4.1 Global Ganciclovir Sales Value by Region: 2020-2025
6.4.2 Global Ganciclovir Sales Value by Region (2026-2031)
6.5 Global Ganciclovir Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Ganciclovir Sales Value (2020-2031)
6.6.2 North America Ganciclovir Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Ganciclovir Sales Value (2020-2031)
6.7.2 Europe Ganciclovir Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Ganciclovir Sales Value (2020-2031)
6.8.2 Asia-Pacific Ganciclovir Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Ganciclovir Sales Value (2020-2031)
6.9.2 South America Ganciclovir Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Ganciclovir Sales Value (2020-2031)
6.10.2 Middle East & Africa Ganciclovir Sales Value Share by Country, 2024 VS 2031
7 Ganciclovir Country-level Sales and Value Analysis
7.1 Global Ganciclovir Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Ganciclovir Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Ganciclovir Sales by Country (2020-2031)
7.3.1 Global Ganciclovir Sales by Country (2020-2025)
7.3.2 Global Ganciclovir Sales by Country (2026-2031)
7.4 Global Ganciclovir Sales Value by Country (2020-2031)
7.4.1 Global Ganciclovir Sales Value by Country (2020-2025)
7.4.2 Global Ganciclovir Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Ganciclovir Sales Value Growth Rate (2020-2031)
7.5.2 USA Ganciclovir Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Ganciclovir Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Ganciclovir Sales Value Growth Rate (2020-2031)
7.6.2 Canada Ganciclovir Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Ganciclovir Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Ganciclovir Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Ganciclovir Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Ganciclovir Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Ganciclovir Sales Value Growth Rate (2020-2031)
7.8.2 Germany Ganciclovir Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Ganciclovir Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Ganciclovir Sales Value Growth Rate (2020-2031)
7.9.2 France Ganciclovir Sales Value Share by Type, 2024 VS 2031
7.9.3 France Ganciclovir Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Ganciclovir Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Ganciclovir Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Ganciclovir Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Ganciclovir Sales Value Growth Rate (2020-2031)
7.11.2 Italy Ganciclovir Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Ganciclovir Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Ganciclovir Sales Value Growth Rate (2020-2031)
7.12.2 Spain Ganciclovir Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Ganciclovir Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Ganciclovir Sales Value Growth Rate (2020-2031)
7.13.2 Russia Ganciclovir Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Ganciclovir Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Ganciclovir Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Ganciclovir Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Ganciclovir Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Ganciclovir Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Ganciclovir Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Ganciclovir Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Ganciclovir Sales Value Growth Rate (2020-2031)
7.16.2 China Ganciclovir Sales Value Share by Type, 2024 VS 2031
7.16.3 China Ganciclovir Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Ganciclovir Sales Value Growth Rate (2020-2031)
7.17.2 Japan Ganciclovir Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Ganciclovir Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Ganciclovir Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Ganciclovir Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Ganciclovir Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Ganciclovir Sales Value Growth Rate (2020-2031)
7.19.2 India Ganciclovir Sales Value Share by Type, 2024 VS 2031
7.19.3 India Ganciclovir Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Ganciclovir Sales Value Growth Rate (2020-2031)
7.20.2 Australia Ganciclovir Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Ganciclovir Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Ganciclovir Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Ganciclovir Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Ganciclovir Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Ganciclovir Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Ganciclovir Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Ganciclovir Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Ganciclovir Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Ganciclovir Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Ganciclovir Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Ganciclovir Sales Value Growth Rate (2020-2031)
7.24.2 Chile Ganciclovir Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Ganciclovir Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Ganciclovir Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Ganciclovir Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Ganciclovir Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Ganciclovir Sales Value Growth Rate (2020-2031)
7.26.2 Peru Ganciclovir Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Ganciclovir Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Ganciclovir Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Ganciclovir Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Ganciclovir Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Ganciclovir Sales Value Growth Rate (2020-2031)
7.28.2 Israel Ganciclovir Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Ganciclovir Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Ganciclovir Sales Value Growth Rate (2020-2031)
7.29.2 UAE Ganciclovir Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Ganciclovir Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Ganciclovir Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Ganciclovir Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Ganciclovir Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Ganciclovir Sales Value Growth Rate (2020-2031)
7.31.2 Iran Ganciclovir Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Ganciclovir Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Ganciclovir Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Ganciclovir Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Ganciclovir Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Bausch & Lomb
8.1.1 Bausch & Lomb Comapny Information
8.1.2 Bausch & Lomb Business Overview
8.1.3 Bausch & Lomb Ganciclovir Sales, Value and Gross Margin (2020-2025)
8.1.4 Bausch & Lomb Ganciclovir Product Portfolio
8.1.5 Bausch & Lomb Recent Developments
8.2 Fresenius Kabi
8.2.1 Fresenius Kabi Comapny Information
8.2.2 Fresenius Kabi Business Overview
8.2.3 Fresenius Kabi Ganciclovir Sales, Value and Gross Margin (2020-2025)
8.2.4 Fresenius Kabi Ganciclovir Product Portfolio
8.2.5 Fresenius Kabi Recent Developments
8.3 HUBEI KEYI
8.3.1 HUBEI KEYI Comapny Information
8.3.2 HUBEI KEYI Business Overview
8.3.3 HUBEI KEYI Ganciclovir Sales, Value and Gross Margin (2020-2025)
8.3.4 HUBEI KEYI Ganciclovir Product Portfolio
8.3.5 HUBEI KEYI Recent Developments
8.4 Luitpold
8.4.1 Luitpold Comapny Information
8.4.2 Luitpold Business Overview
8.4.3 Luitpold Ganciclovir Sales, Value and Gross Margin (2020-2025)
8.4.4 Luitpold Ganciclovir Product Portfolio
8.4.5 Luitpold Recent Developments
8.5 Tiantianming
8.5.1 Tiantianming Comapny Information
8.5.2 Tiantianming Business Overview
8.5.3 Tiantianming Ganciclovir Sales, Value and Gross Margin (2020-2025)
8.5.4 Tiantianming Ganciclovir Product Portfolio
8.5.5 Tiantianming Recent Developments
8.6 Huatai Pharmaceutical
8.6.1 Huatai Pharmaceutical Comapny Information
8.6.2 Huatai Pharmaceutical Business Overview
8.6.3 Huatai Pharmaceutical Ganciclovir Sales, Value and Gross Margin (2020-2025)
8.6.4 Huatai Pharmaceutical Ganciclovir Product Portfolio
8.6.5 Huatai Pharmaceutical Recent Developments
8.7 Tungshun Group
8.7.1 Tungshun Group Comapny Information
8.7.2 Tungshun Group Business Overview
8.7.3 Tungshun Group Ganciclovir Sales, Value and Gross Margin (2020-2025)
8.7.4 Tungshun Group Ganciclovir Product Portfolio
8.7.5 Tungshun Group Recent Developments
8.8 Roche
8.8.1 Roche Comapny Information
8.8.2 Roche Business Overview
8.8.3 Roche Ganciclovir Sales, Value and Gross Margin (2020-2025)
8.8.4 Roche Ganciclovir Product Portfolio
8.8.5 Roche Recent Developments
8.9 Luoxin
8.9.1 Luoxin Comapny Information
8.9.2 Luoxin Business Overview
8.9.3 Luoxin Ganciclovir Sales, Value and Gross Margin (2020-2025)
8.9.4 Luoxin Ganciclovir Product Portfolio
8.9.5 Luoxin Recent Developments
8.10 Wuhan Hualong Bio-pharmaceutical
8.10.1 Wuhan Hualong Bio-pharmaceutical Comapny Information
8.10.2 Wuhan Hualong Bio-pharmaceutical Business Overview
8.10.3 Wuhan Hualong Bio-pharmaceutical Ganciclovir Sales, Value and Gross Margin (2020-2025)
8.10.4 Wuhan Hualong Bio-pharmaceutical Ganciclovir Product Portfolio
8.10.5 Wuhan Hualong Bio-pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Ganciclovir Value Chain Analysis
9.1.1 Ganciclovir Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Ganciclovir Sales Mode & Process
9.2 Ganciclovir Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Ganciclovir Distributors
9.2.3 Ganciclovir Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.